# Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

> **NCT02921893** · EARLY_PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 21 (actual)

## Conditions studied

- Plasmacytoma
- POEMS Syndrome

## Interventions

- **DRUG:** Dexamethasone
- **DRUG:** Ixazomib Citrate
- **DRUG:** Lenalidomide
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT02921893
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-31
- **Primary completion:** 2022-04-21
- **Final completion:** 2024-05-13
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02921893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02921893, "Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02921893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*